

Antonella Olivero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7337407/publications.pdf>

Version: 2024-02-01

27
papers

455
citations

566801

15
h-index

713013

21
g-index

27
all docs

27
docs citations

27
times ranked

661
citing authors

#	ARTICLE	IF	CITATIONS
1	Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 635.	1.0	12
2	Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification. <i>Biomedicines</i> , 2022, 10, 792.	1.4	4
3	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. <i>Biology</i> , 2021, 10, 215.	1.3	4
4	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 2305.	1.7	24
5	Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study. <i>Journal of Clinical Virology</i> , 2021, 142, 104932.	1.6	19
6	The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. <i>Journal of Advanced Research</i> , 2021, 33, 183-187.	4.4	16
7	Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report. <i>Diagnostics</i> , 2021, 11, 2185.	1.3	2
8	Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2776.	1.7	14
9	Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8838.	1.8	22
10	Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report. <i>Journal of Clinical Medicine</i> , 2020, 9, 2353.	1.0	18
11	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. <i>Cancers</i> , 2020, 12, 3218.	1.7	27
12	On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 800.	1.0	29
13	Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114985.	0.8	14
14	Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors. <i>Journal of Hepatology</i> , 2019, 70, 793-795.	1.8	4
15	Reply to: "Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition". <i>Journal of Hepatology</i> , 2019, 70, 559-560.	1.8	0
16	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. <i>Minerva Medica</i> , 2019, 110, 401-409.	0.3	22
17	Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience. <i>Minerva Gastroenterologica E Dietologica</i> , 2019, 65, 77-78.	2.2	3
18	Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8 ⁺ T Cells. <i>Journal of Virology</i> , 2018, 92, .	1.5	23

#	ARTICLE	IF	CITATIONS
19	Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D infected patients treated with nucleos(t)ide analogues or pegylated interferon. Hepatology Research, 2017, 47, 747-754.	1.8	20
20	Role of serum hepatitis B core-related antigen in chronic hepatitis B infection. Minerva Biotechnology and Biomolecular Research, 2017, 30, .	0.3	3
21	Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. Panminerva Medica, 2017, 59, 283-289.	0.2	35
22	Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. Digestive and Liver Disease, 2016, 48, 55-61.	0.4	19
23	Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: Correlation with the ARCHITECT quantitative assays. Journal of Clinical Virology, 2014, 60, 341-346.	1.6	22
24	IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. World Journal of Gastroenterology, 2014, 20, 13146.	1.4	20
25	Multiple courses of G-CSF in patients with decompensated cirrhosis: consistent mobilization of immature cells expressing hepatocyte markers and exploratory clinical evaluation. Hepatology International, 2013, 7, 1075-1083.	1.9	21
26	Hepatitis Delta Virus Diagnosis. Seminars in Liver Disease, 2012, 32, 220-227.	1.8	50
27	Antimicrotubular effect of calvatic acid and of some related compounds. Cell Biochemistry and Function, 1995, 13, 231-238.	1.4	8